Diagnos Laboratorium Utama Tbk. vs Saraswanti Indoland Development Tbk. — how do they compare? Diagnos Laboratorium Utama Tbk. trades at Rp224 (market cap 310.75B, 963.6K 24h volume), while Saraswanti Indoland Development Tbk. trades at Rp93 (market cap 490.04B, 960.5K 24h volume). The key difference: Saraswanti Indoland Development Tbk. is the larger of the two by market cap, and Diagnos Laboratorium Utama Tbk. is more actively traded (963.6K versus 960.5K). Which is the better fit depends on your goals.
| DGNS | SWID | |
|---|---|---|
Market Cap | 310.75B | 490.04B |
Volume | 963.6K | 960.5K |
Lot | 9.64K | 9.61K |
Turnover | 217.67M | 87.63M |
Average Price | 225.89 | 91.23 |
Value | 217.67M | 87.63M |
Indicative Equilibrium Price | 226 | 93 |
Indicative Equilibrium Volume | 1K | 12 |
Trailing returns across standard periods
Latest headlines on both assets
PT Diagnos Laboratorium Utama Tbk (the “Company”) was established in the Republic of Indonesia on August 29, 2007 under framework of the Domestic Capital Investment Law No. 6 Year 1968 based on Deed No.17 dated August 29, 2007, of Martinef, S.H., M.Si., Notary in Bekasi. The Company started its commercial operation in 2008.
Read more on DGNS →PT Saraswanti Indoland Development Tbk ( The Company) was established on August 2, 2010 based on the Deed of Notary Ismaryani, SH, MKn. Number : 01. The deed of establishment of the Company was approved by the Minister of Law and Human Rights of the Republic of Indonesia number: AHU41610.AH.01.01.Tahun 2010. The Company started its commercial operations in 2011.
Read more on SWID →